June 11, 2024
The panel reviews the TN-10 trial investigating teplizumab, focusing on patient inclusion criteria, patient outcomes, and adverse reactions.
June 11, 2024
Diabetes specialists from UCSD discuss teplizumab, the first FDA-approved drug for delaying onset of T1D, highlighting its benefits and mechanism of action.
June 11, 2024
Schafer Boeder, MD and Andrea Stallings, PA delve into the intricacies of autoantibody screening tests for T1D with detailed insights on their methodologies, interpretation nuances, and practical analysis considerations.
June 11, 2024
Following a couple of audience polling questions, Andrea Stallings, PA and her UCSD colleagues, comment on identifying suitable candidates for T1D screening, understanding autoantibodies involved in this condition, and determining when to rescreen those at risk for disease progression.
June 11, 2024
Addressing the significance of acting early in T1D care, a group of diabetes experts delve into the impact of delaying intervention during stage 2 of the condition.
June 11, 2024
Schafer Boeder, MD and his colleagues provide a comprehensive overview of the stages of T1D in patients with diabetes, highlighting the various signs and symptoms associated with each stage.
June 11, 2024
A panel of experts on diabetes management introduce themselves and provide an overview of the condition, highlighting risk factors, disease burden, and the benefits of collaborative care.